2014: Benefit assessment in studies with allowed treatment switching

Presentations (German):

  •  The ethical dimensions of studies with allowed treatment switching
  •  Criteria for treatment switching in oncological studies
  •  The role of the Federal Institute for Drugs and Medical Devices (BfArM) in the planning, authorization and acceptance of clinical studies and their results in oncology
  •  Evaluation of treatment switching in the Institute’s assessments
  •  Methods to estimate survival time after treatment switching in oncology – overview and practical considerations
  •  Adjustment of overall survival (OS) after crossover – aspects from the perspective of the benefit assessment

Programme and Abstracts